search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


25 resulaten gevonden voor Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) in trials

A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor Pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation
- TRIAL ID
NTR6751
- ACRONYMHOVON 134 MF
Carfilzomib and lenalidomide-based treatment for younger and elderly newly diagnosed primary plasma cell leukemia patients.
- TRIAL ID
NTR5350
- ACRONYMHOVON 129 PCL
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib.
- TRIAL ID
NTR5349
- ACRONYMHOVON 114 MM
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial.
- TRIAL ID
NTR4910
- ACRONYMHOVON 126 MM
Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma
- TRIAL ID
NTR4602
- ACRONYMHOVON 127 BL
Efficacy and safety of first-line therapy with chlorambucil, rituximab and lenalidomide (Revlimid®) (CR2) in elderly patients and young frail patients with advanced Chronic Lymphocytic Leukemia (CLL): A phase II trial.
- TRIAL ID
NTR3052
- ACRONYMHOVON 109 CLL
ReBeL study: A randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma. A HOVON/GLSG study.
- TRIAL ID
NTR3028
- ACRONYMHOVON 110 FL / GLSG
The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: A randomized phase II study.
- TRIAL ID
NTR2929
- ACRONYMHOVON 107 MOBILIZATION
Rituximab in Primary Central Nervous system Lymphoma. A randomized HOVON / ALLG intergroup study.
- TRIAL ID
NTR2427
- ACRONYMHOVON 105 PCNSL
Lenalidomide maintenance following tandem autologous stem cell and non myeloablative allogeneic transplantation for patients with multiple myeloma <= 66 years.
- TRIAL ID
NTR1645
- ACRONYMHOVON 76 MM
Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS >= 1.5)
- TRIAL ID
NTR1446
- ACRONYMHOVON 92 AML
Clinical effectiveness and safety of pooled, random donor platelet concentrates, leucoreduced and stored up to seven days either in additive solution with and without pathogen reduction or plasma in hemato-oncological patients.
- TRIAL ID
NTR861
- ACRONYMHOVON 82
An open label randomized controlled study in elderly subjects with previously untreated acute myelogenous leukaemia, comparing treatment groups randomised to receive daunorubicin and cytarabine or daunorubicin, cytarabine and PSC-833.
- TRIAL ID
NTR360
- ACRONYMHOVON 31 AML / Novartis PSC C 302-E-00
Myelo-ablative chemo/radiotherapy and autologous stem cell transplantation as compared to only chemotherapy in patients with multiple myeloma.
- TRIAL ID
NTR321
- ACRONYMHOVON 24 MM
Effect of recombinant G-CSF on the results of chemotherapy (CHOP) in elderly patients with intermediate-/high-grade Non-Hodgkin’s Lymphoma. A prospective phase III study.
- TRIAL ID
NTR320
- ACRONYMHOVON 25 NHL
Intensified CHOP of 12-weeks duration plus G-CSF as compared with standard CHOP of 24-weeks duration for patients with intermediate-prognosis Non Hodgkin’s Lymphoma.
- TRIAL ID
NTR239
- ACRONYMHOVON 26 NHL
A randomized phase III study on the effect of Thalidomide combined with Adriamycin, Dexamethasone (AD) and High Dose Melphalan in patients with multiple myeloma.
- TRIAL ID
NTR238
- ACRONYMHOVON 50 MM / GMMG-HD3
A randomized phase III study of i.v. zoledronate (administered for 12 versus 36 months) as an adjunct to standard therapies in the treatment of multiple myeloma. A phase III study.
- TRIAL ID
NTR233
- ACRONYMHOVON 50 MM
Randomized phase III study in elderly patients with a multiple myeloma on the value of Thalidomide added to Melphalan plus Prednisone.
- TRIAL ID
NTR232
- ACRONYMHOVON 49 MM
Randomized induction and post induction therapy in adult patients (<= 60 yrs of age) with acute myelocytic leukemia (AML) or refractory anemia with excess of blasts (RAEB, RAEB-t) with IPSS score >= 1.5.
- TRIAL ID
NTR230
- ACRONYMHOVON/SAKK 42 AML
Early intensification by (un)related allogeneic or autologous stem cell transplantation in adult acute lymphoblastic leukemia. A phase II study.
- TRIAL ID
NTR228
- ACRONYMHOVON 37 ALL
A randomized phase III study on the effect of Bortezomib combined with Adriamycin, Dexamethasone (AD) for induction treatment, followed by High Dose Melphalan and Bortezomib alone during maintenance in patients with multiple myeloma.
- TRIAL ID
NTR213
- ACRONYMHOVON 65 MM / GMMG-HD4
Anti-CD20 treatment of relapsed or refractory Immune Thrombocytopenic Purpura (ITP) after first line corticosteroid treatment.
- TRIAL ID
NTR211
- ACRONYMHOVON 64 ITP
A randomized phase III study on the effect of the chimeric anti-CD20 monoclonal antibody (MabThera) during sequential chemotherapy followed by autologous stem cell transplantation in patients with relapsed or progressive B-cell non-Hodgkin’s lymphoma.
- TRIAL ID
NTR188
- ACRONYMHOVON 44 NHL
A randomized phase III study of chimeric anti-CD20 monoclonal antibody (Rituximab) with 2-weekly CHOP chemotherapy (CHOP 14) in elderly patients with intermediate- or high-risk non-Hodgkin’s lymphoma.
- TRIAL ID
NTR184
- ACRONYMHOVON 46 NHL